Literature DB >> 34336471

Optic Disc Dose Comparison Between 125I and 103Pd Collaborative Ocular Melanoma Study (COMS) Plaques Based on Current Clinical Practice.

Yongsook C Lee1, Shih-Chi Lin2, Yongbok Kim3.   

Abstract

Purpose The purpose of this study is to compare optic disc dose (ODD) between 125I and 103Pd Collaborative Ocular Melanoma Study (COMS) plaques in ocular brachytherapy. Methods A previously validated in-house brachytherapy dose calculation program was used for ODD calculations. ODD was calculated as a function of tumor margin-to-optic disc distance (DT) up to 5 mm for various tumor basal dimensions (BDs), for a prescription depth of 5 mm, and for standard and notched COMS plaques loaded with 125I (model: IAI-125A) and 103Pd (model: IAPd-103A) seeds. ODD calculations were repeated for prescription depths from 2 mm to 10 mm in 1 mm intervals. A prescribed dose of 85 Gy (irradiation time: 120 hours) was normalized to each prescription depth. Dose conversion factors (DCFs) for each prescription depth were calculated by taking a ratio of [total reference air kerma (TRAK) per seed]prescription depth to [TRAK per seed]5 mm. ODD reduction by notched COMS plaques was calculated for each prescription depth by subtracting ODD for notched COMS plaques from ODD for standard COMS plaques. Results Trends of ODD as a function of DT for various BDs are similar between the two seed types in both standard and notched COMS plaques. However, due to the energy difference, there exists a transition distance (dt) for each BD in each plaque at which ODD for 125I COMS plaques equals that for 103Pd COMS plaques. For small BDs, at DT <dt, ODD for 103Pd COMS plaques is higher than that for 125I COMS plaques while at DT >dt, the opposite is observed. For the largest 1-3 BD(s), contrarily, dt occurs within the tumor, and thus, ODD for 125I COMS plaquesis always higher. Trends of ODD reduction by notched COMS plaques as a function of DT for various BDs are the same for the two seed types except that maximum ODD reduction by 103Pd COMS notched plaques is larger. DCF increases with increasing prescription depth for both seed types. Conclusions There exist ODD differences between 125I and 103Pd COMS plaques and the differences depend on DT, BD, plaque size, and prescription depth.
Copyright © 2021, Lee et al.

Entities:  

Keywords:  103pd; 125i; coms plaques; ocular brachytherapy; optic disc dose

Year:  2021        PMID: 34336471      PMCID: PMC8317005          DOI: 10.7759/cureus.15980

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  15 in total

1.  Comparison of dose calculation methods for brachytherapy of intraocular tumors.

Authors:  Mark J Rivard; Sou-Tung Chiu-Tsao; Paul T Finger; Ali S Meigooni; Christopher S Melhus; Firas Mourtada; Mary E Napolitano; D W O Rogers; Rowan M Thomson; Ravinder Nath
Journal:  Med Phys       Date:  2011-01       Impact factor: 4.071

2.  Model-based dose calculations for COMS eye plaque brachytherapy using an anatomically realistic eye phantom.

Authors:  Marielle Lesperance; M Inglis-Whalen; R M Thomson
Journal:  Med Phys       Date:  2014-02       Impact factor: 4.071

3.  Outcomes of choroidal melanomas treated with eye physics: a 20-year review.

Authors:  Jesse L Berry; Savita V Dandapani; Marta Stevanovic; Thomas C Lee; Melvin Astrahan; A Linn Murphree; Jonathan W Kim
Journal:  JAMA Ophthalmol       Date:  2013-11       Impact factor: 7.389

4.  Palladium-103 plaque radiotherapy for choroidal melanoma: an 11-year study.

Authors:  Paul T Finger; Anthony Berson; Tracy Ng; Andrzej Szechter
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-12-01       Impact factor: 7.038

5.  Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.

Authors:  Sou-Tung Chiu-Tsao; Melvin A Astrahan; Paul T Finger; David S Followill; Ali S Meigooni; Christopher S Melhus; Firas Mourtada; Mary E Napolitano; Ravinder Nath; Mark J Rivard; D W O Rogers; Rowan M Thomson
Journal:  Med Phys       Date:  2012-10       Impact factor: 4.071

6.  Palladium-103 plaque radiation therapy for American Joint Committee on cancer T3- and T4-staged choroidal melanomas.

Authors:  Ekaterina Semenova; Paul T Finger
Journal:  JAMA Ophthalmol       Date:  2014-02       Impact factor: 7.389

7.  Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients.

Authors:  Paul T Finger; Kimberly J Chin; Greg Duvall
Journal:  Ophthalmology       Date:  2009-02-25       Impact factor: 12.079

8.  Optic disc dose reduction in ocular brachytherapy using 125 I notched COMS plaques: A simulation study based on current clinical practice.

Authors:  Yongsook C Lee; Shih-Chi Lin; Yongbok Kim
Journal:  J Appl Clin Med Phys       Date:  2020-07-12       Impact factor: 2.102

9.  Secondary Enucleations for Uveal Melanoma: A 7-Year Retrospective Analysis.

Authors:  Ido Didi Fabian; Oren Tomkins-Netzer; Ian Stoker; Amit K Arora; Mandeep S Sagoo; Victoria M L Cohen
Journal:  Am J Ophthalmol       Date:  2015-09-04       Impact factor: 5.258

10.  A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using 125I COMS plaques.

Authors:  Yongsook C Lee; Shih-Chi Lin; Yongbok Kim
Journal:  Radiat Oncol       Date:  2018-11-13       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.